Related Experiment Video
Updated: Oct 5, 2025
06:37
Pluripotent Stem Cell Derived Cardiac Cells for Myocardial Repair
Published on: February 3, 2017
8.5K
Emerging therapeutic targets for cardiac hypertrophy
Alexander J Winkle1,2, Drew M Nassal1,2, Rebecca Shaheen1,2
1The Frick Center for Heart Failure and Arrhythmia, The Dorothy M. Davis Heart and Lung Research Institute, the Ohio State University Wexner Medical Center, Columbus, OH, USA.
Expert Opinion on Therapeutic Targets
|January 25, 2022
Summary
Cardiac hypertrophy, a key factor in heart disease, involves complex molecular mechanisms. Understanding myocyte growth orientation offers new therapeutic strategies for preventing cardiac pathology.
Area of Science:
- Cardiovascular Disease Research
- Molecular Cardiology
- Cellular Biology
Background:
- Cardiac hypertrophy is linked to poor outcomes in cardiovascular diseases.
- Molecular mechanisms of hypertrophy are increasingly understood, but the connection to specific heart growth patterns remains unclear.
- Current strategies for preventing hypertrophic pathology are debated.
Purpose of the Study:
- To review molecular mechanisms of cardiac hypertrophy.
- To focus on factors influencing myocyte growth orientation and heart function.
- To explore therapeutic potential in directing myocyte growth orientation.
Main Methods:
- Literature review of publications on cardiac hypertrophy.
- PubMed search with open-ended date range.
- Focus on spectrin-based cytoskeleton's role in myocyte dimensions.
Main Results:
- The spectrin-based cytoskeleton regulates myocyte dimensions, not hypertrophy itself.
- Understanding myocyte growth orientation is crucial for therapeutic development.
- Novel therapeutic approaches may involve directing myocyte growth orientation.
Conclusions:
- Precision in describing myocyte and heart changes is needed for new therapies.
- Computational modeling and refined experimental methods will advance understanding of cardiac hypertrophy.
- Further research can improve therapeutic strategies for cardiac hypertrophy and heart disease.
Related Concept Videos
01:27Transducer Mechanism: Enzyme-Linked Receptors
3.1K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
3.1K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
551
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
551
01:29Heart Failure II: Pathophysiology
92
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
92
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
80
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
80
01:29Cardiomyopathy V: Interprofessional Care
57
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
57
01:30Cardiomyopathy II: Dilated Cardiomyopathy
52
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
52